Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 ...

OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...

In a recent study, more than 40% of patients with relapsed or refractory germ cell tumors experienced a clinical benefit with cabozantinib.

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens ...

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...

Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or ...